OUR TEAM
At the heart of Pairidex® is a team of passionate problem-solvers working to make blood cancer care smarter, faster, and more compassionate. Our expertise spans genomics, oncology, and diagnostics, but it’s our shared dedication to making a real-world difference that sets us apart.
Paul Kortschak, MBA, MS, JD
CEO
Over 25 years driving market share, revenue, and profit growth in molecular diagnostic, clinical diagnostic, companion diagnostic and healthcare IT.
Andrew Young, MD, PhD
Founder & CSO
Assistant Professor of Medicine in the Division of Hematology at WashU. Expert in rare mutation detection and clonal evolution.
Allyson Mayer, PhD
Interim COO
Principal at BioGenerator Ventures. Biologist and company builder with experience in startup operations.
Drew Hughes, MD, PhD
Medical Director
Assistant Professor in Pathology and Immunology. Expert in molecular genetic pathology.
Ellie Wilson, PhD
Senior Scientist
PhD in Molecular Genetics and Genomics. Former clinical research associate at HematoLogics Inc.
SOFIA PORTER
Senior Research Associate
Bachelors degree in Neuroscience with 10 years of molecular biology and lab management experience in academic, industry and startup laboratory settings.
Farhan William
Bachelor’s degree in biology with 4+ years of molecular biology and project management experience in a startup setting.
OUR BOARD
Pairidex’s Board of Directors and Scientific Advisory Board are composed of dedicated experts in their fields. Together they help shape our strategies and support our mission to advance blood cancer detection and monitoring.
Andrew Young, MD, PhD
Founder & CSO
Instructor of Medicine in the Division of Hematology at WashU. Expert in rare mutation detection, ddPCR, and clonal evolution.
Jim McCarter, MD, PhD
Board Director
Sr. Managing Director of BioGenerator Ventures. Previous leadership roles at Abbott, Virta Health; founded & exited genomics startup Divergence.
Todd Druley, MD, PhD
Board Director
CSO of Hematology at Danaher Corporation with expertise in developing blood cancer diagnostics. Previous CMO of Mission Bio, ArcherDx, and ANGLE Biosciences.
Grant Challen, PhD
Co-Founder & Scientific Advisor
WashU Professor in the Division of Oncology. Expert in stem cell biology and leukemia genomics.
Eric Green, MD, PhD
Scientific Advisor
Physician scientist, genomics researcher, Human Genome Project participant, and former Director of the National Human Genome Research Institute at the U.S. National Institutes of Health.
Jesse Salk, MD, PhD
Scientific Advisor
Medical oncologist and founder of TwinStrand Biosciences. Expert in DNA seq & rare variant detection.
Lulu Sun, MD, PhD
Scientific Advisor
Assistant Professor in Pathology and Immunology. Experience with CAP/CLIA processes.
The Pairidex tumor-informed droplet digital PCR fusion assay offers superior sensitivity and rapid turnaround time – at a cost-effective price compared to current gold standard tests. It’s an ideal assay for cancer surveillance or therapeutic monitoring for gene fusion driven disease.
Todd Druley, MD, PhD
CSO of Hematology, Danaher Corporation
The Pairidex tumor-informed droplet digital PCR fusion assay offers superior sensitivity and rapid turnaround time – at a cost-effective price compared to current gold standard tests. It’s an ideal assay for cancer surveillance or therapeutic monitoring for gene fusion driven disease.
Todd Druley, MD, PhD
CSO of Hematology, Danaher Corporation
The Pairidex tumor-informed droplet digital PCR fusion assay offers superior sensitivity and rapid turnaround time – at a cost-effective price compared to current gold standard tests. It’s an ideal assay for cancer surveillance or therapeutic monitoring for gene fusion driven disease.
Andrew Young, MD, PhD, Founder & CEO Pairidex
Connect with us
Reach out now for a personalized quote or to discover how we can support your goals.